For the quarter ended December 2025, Albemarle (ALB) reported revenue of $1.43 billion, up 15.9% over the same period last year. EPS came in at -$0.53, compared to -$1.09 in the year-ago quarter.
The reported revenue represents a surprise of +5.8% over the Zacks Consensus Estimate of $1.35 billion. With the consensus EPS estimate being -$0.40, the EPS surprise was -33%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Albemarle performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Net Sales- Energy Storage: $759.06 million compared to the $716.89 million average estimate based on five analysts. The reported number represents a change of +23.1% year over year.
- Net Sales- Ketjen: $320.07 million versus the five-analyst average estimate of $296.35 million. The reported number represents a year-over-year change of +13.5%.
- Net Sales- Specialties: $348.9 million versus the five-analyst average estimate of $348.66 million. The reported number represents a year-over-year change of +4.8%.
- Adjusted EBITDA- Corporate: $-16.54 million versus $-15.46 million estimated by five analysts on average.
- Adjusted EBITDA- Ketjen: $49.68 million versus $35.01 million estimated by five analysts on average.
- Adjusted EBITDA- Specialties: $68.55 million compared to the $52.12 million average estimate based on five analysts.
- Adjusted EBITDA- Energy Storage: $167.06 million compared to the $159.67 million average estimate based on five analysts.
View all Key Company Metrics for Albemarle here>>>
Shares of Albemarle have returned -4.7% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Albemarle Corporation (ALB) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
